Parenteral estrogens for prostate cancer

Can a new route of administration overcome old toxicities?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) is the mainstay of management of advanced-stage prostate cancer and recently has been shown to improve survival when administered in earlier stages of the disease. The oncologic benefits of ADT might be partially offset, however, by a reduction in quality of life because of adverse effects. In addition to the well-recognized adverse consequences of ADT, recent evidence suggests that ADT is associated with dyslipidemia, impaired glucose metabolism, adverse body compositional changes, and osteoporosis. Therefore, there is a pressing need to develop less toxic forms of ADT. A novel approach to this problem is the use of estrogen to induce androgen suppression. Whereas oral estrogen therapy is known to be associated with thromboembolic complications, studies of parenteral estrogen in men with prostate cancer suggest that the use of parenteral estrogen achieves target androgen suppression, does not adversely affect prothrombotic protein levels, and is not associated with adverse metabolic, skeletal, and body compositional changes when compared with conventional ADT. Herein, we review the data for parenteral estrogen use in prostate cancer, the antineoplastic mechanisms of action of estrogen in prostate cancer, the potential advantages of parenteral estrogen compared with conventional ADT, and the remaining barriers in the use of parenteral estrogen in prostate cancer.

Original languageEnglish (US)
Pages (from-to)198-205
Number of pages8
JournalClinical Genitourinary Cancer
Volume5
Issue number3
DOIs
StatePublished - Dec 2006

Fingerprint

Androgens
Prostatic Neoplasms
Estrogens
Therapeutics
Poisons
Dyslipidemias
Antineoplastic Agents
Osteoporosis
Quality of Life
Glucose
Survival

Keywords

  • Androgen deprivation therapy
  • Hormonal therapy
  • Transdermal estradiol

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{5e57ec0168274246b9ab51a66759f47f,
title = "Parenteral estrogens for prostate cancer: Can a new route of administration overcome old toxicities?",
abstract = "Androgen deprivation therapy (ADT) is the mainstay of management of advanced-stage prostate cancer and recently has been shown to improve survival when administered in earlier stages of the disease. The oncologic benefits of ADT might be partially offset, however, by a reduction in quality of life because of adverse effects. In addition to the well-recognized adverse consequences of ADT, recent evidence suggests that ADT is associated with dyslipidemia, impaired glucose metabolism, adverse body compositional changes, and osteoporosis. Therefore, there is a pressing need to develop less toxic forms of ADT. A novel approach to this problem is the use of estrogen to induce androgen suppression. Whereas oral estrogen therapy is known to be associated with thromboembolic complications, studies of parenteral estrogen in men with prostate cancer suggest that the use of parenteral estrogen achieves target androgen suppression, does not adversely affect prothrombotic protein levels, and is not associated with adverse metabolic, skeletal, and body compositional changes when compared with conventional ADT. Herein, we review the data for parenteral estrogen use in prostate cancer, the antineoplastic mechanisms of action of estrogen in prostate cancer, the potential advantages of parenteral estrogen compared with conventional ADT, and the remaining barriers in the use of parenteral estrogen in prostate cancer.",
keywords = "Androgen deprivation therapy, Hormonal therapy, Transdermal estradiol",
author = "Jennifer Lycette and Bland, {Lisa B.} and Mark Garzotto and Beer, {Tomasz (Tom)}",
year = "2006",
month = "12",
doi = "10.3816/CGC.2006.n.037",
language = "English (US)",
volume = "5",
pages = "198--205",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Parenteral estrogens for prostate cancer

T2 - Can a new route of administration overcome old toxicities?

AU - Lycette, Jennifer

AU - Bland, Lisa B.

AU - Garzotto, Mark

AU - Beer, Tomasz (Tom)

PY - 2006/12

Y1 - 2006/12

N2 - Androgen deprivation therapy (ADT) is the mainstay of management of advanced-stage prostate cancer and recently has been shown to improve survival when administered in earlier stages of the disease. The oncologic benefits of ADT might be partially offset, however, by a reduction in quality of life because of adverse effects. In addition to the well-recognized adverse consequences of ADT, recent evidence suggests that ADT is associated with dyslipidemia, impaired glucose metabolism, adverse body compositional changes, and osteoporosis. Therefore, there is a pressing need to develop less toxic forms of ADT. A novel approach to this problem is the use of estrogen to induce androgen suppression. Whereas oral estrogen therapy is known to be associated with thromboembolic complications, studies of parenteral estrogen in men with prostate cancer suggest that the use of parenteral estrogen achieves target androgen suppression, does not adversely affect prothrombotic protein levels, and is not associated with adverse metabolic, skeletal, and body compositional changes when compared with conventional ADT. Herein, we review the data for parenteral estrogen use in prostate cancer, the antineoplastic mechanisms of action of estrogen in prostate cancer, the potential advantages of parenteral estrogen compared with conventional ADT, and the remaining barriers in the use of parenteral estrogen in prostate cancer.

AB - Androgen deprivation therapy (ADT) is the mainstay of management of advanced-stage prostate cancer and recently has been shown to improve survival when administered in earlier stages of the disease. The oncologic benefits of ADT might be partially offset, however, by a reduction in quality of life because of adverse effects. In addition to the well-recognized adverse consequences of ADT, recent evidence suggests that ADT is associated with dyslipidemia, impaired glucose metabolism, adverse body compositional changes, and osteoporosis. Therefore, there is a pressing need to develop less toxic forms of ADT. A novel approach to this problem is the use of estrogen to induce androgen suppression. Whereas oral estrogen therapy is known to be associated with thromboembolic complications, studies of parenteral estrogen in men with prostate cancer suggest that the use of parenteral estrogen achieves target androgen suppression, does not adversely affect prothrombotic protein levels, and is not associated with adverse metabolic, skeletal, and body compositional changes when compared with conventional ADT. Herein, we review the data for parenteral estrogen use in prostate cancer, the antineoplastic mechanisms of action of estrogen in prostate cancer, the potential advantages of parenteral estrogen compared with conventional ADT, and the remaining barriers in the use of parenteral estrogen in prostate cancer.

KW - Androgen deprivation therapy

KW - Hormonal therapy

KW - Transdermal estradiol

UR - http://www.scopus.com/inward/record.url?scp=33846677686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846677686&partnerID=8YFLogxK

U2 - 10.3816/CGC.2006.n.037

DO - 10.3816/CGC.2006.n.037

M3 - Article

VL - 5

SP - 198

EP - 205

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -